Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection

Rachel Y. Chang, Jennifer Wong, Ash Mathai, Sandra Morales, Elizabeth Kutter, Warwick Britton, Jian Li, Hak Kim Chan

Research output: Contribution to journalArticleResearchpeer-review

36 Citations (Scopus)


The potential of bacteriophage therapy for the treatment of pulmonary infections caused by antibiotic-resistant bacteria has been well recognised. The purpose of this study was to investigate the effect of excipients on stabilisation and aerosolisation of spray dried powders of morphologically different phages – PEV podovirus and PEV myovirus. Seven anti-pseudomonal phages were screened against 90 clinical strains of bacterial hosts and three of the phages were selected for formulation study based on the host range. Design of experiments was utilised to assess the effect of different excipients on the stabilisation and aerosolisation of spray dried phages. Both podovirus and myovirus phages were stable in spray dried formulations containing trehalose or lactose and leucine as excipients with less than 1-log10 titre reduction during spray drying, with lactose providing superior phage protection over trehalose. Furthermore, the spray dried phage formulations dispersed in an Osmohaler at 85 L/min produced a high fine particle fraction of over 50%. The results showed that the phages in this study can form respirable dry powder phage formulations using the same excipient composition. Spray dried various types of lytic phages hold significant potential for the treatment of pulmonary infections.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Publication statusPublished - 1 Dec 2017


  • Antibiotic-resistant bacteria
  • Bacteriophage therapy
  • Biotherapeutics
  • Powder aerosols
  • Pulmonary infections

Cite this